The estimated Net Worth of James Niedel is at least 42.3 百万$ dollars as of 9 September 2014. James Niedel owns over 1,099,949 units of Chimerix Inc stock worth over 899,631$ and over the last 12 years James sold CMRX stock worth over 41,410,188$.
James has made over 2 trades of the Chimerix Inc stock since 2013, according to the Form 4 filled with the SEC. Most recently James sold 1,099,949 units of CMRX stock worth 32,327,501$ on 9 September 2014.
The largest trade James's ever made was selling 1,099,949 units of Chimerix Inc stock on 9 September 2014 worth over 32,327,501$. On average, James trades about 210,694 units every 40 days since 2013. As of 9 September 2014 James still owns at least 1,046,082 units of Chimerix Inc stock.
You can see the complete history of James Niedel stock trades at the bottom of the page.
James's mailing address filed with the SEC is C/O CHIMERIX, INC., 2505 MERIDIAN PARKWAY, SUITE 340, DURHAM,, NC, 27713.
Over the last 12 years, insiders at Chimerix Inc have traded over 133,441,183$ worth of Chimerix Inc stock and bought 1,129,869 units worth 4,757,752$ . The most active insiders traders include Patrick Machado、Pharmaceuticals, Inc. Cantex、Ernest Mario. On average, Chimerix Inc executives and independent directors trade stock every 25 days with the average trade being worth of 72,060$. The most recent stock trade was executed by Michael T. Andriole on 8 August 2024, trading 1,285 units of CMRX stock currently worth 1,067$.
led by an experienced antiviral drug development team, chimerix is developing novel oral antiviral therapeutics with the potential to improve quality of life for patients in multiple settings, including transplant, oncology, acute care and global health. the company’s proprietary lipid technology has given rise to two clinical stage compounds, cmx001 and cmx157, which have demonstrated the potential for enhanced activity, bioavailability and safety compared to currently approved drugs. chimerix’s lead compound, cmx001, is a broad spectrum lipid acyclic nucleoside phosphonate that inhibits double-stranded dna (dsdna) viruses including cytomegalovirus (cmv), adenovirus, bk virus, herpes simplex virus and variola (smallpox). cmx001 has completed phase 2 clinical development for the prophylaxis of cmv and is in phase 2 development for the preemption and treatment of adenovirus infection in hematopoietic stem cell transplant (hsct) recipients. to date, more than 750 patients have been dosed
Chimerix Inc executives and other stock owners filed with the SEC include: